Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU leaves phenolphthalein action decision to individual member states.

This article was originally published in The Tan Sheet

Executive Summary

EU PHENOLPHTHALEIN WITHDRAWAL DECISION LEFT TO INDIVIDUAL MEMBER STATES in a position paper on the genotoxic and carcinogenic potential of phenolphthalein recently issued by the European Medicines Evaluation Agency's Committee for Proprietary Medicinal Products. The position paper reviews FDA's interpretation of National Toxicology Program data on phenolphthalein, advising that the CPMP report "can be used by National Competent Authorities in their considerations of any restriction of availability of phenolphthalein-containing medicinal products on national markets."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087937

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel